{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:40:40Z","timestamp":1792014040745,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bbmt.2020.04.028","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T19:01:42Z","timestamp":1589569302000},"page":"1492-1496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion"],"prefix":"10.1016","volume":"26","author":[{"given":"Marcos","family":"Arango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.04.028_bib0001","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/tid.12455","article-title":"Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients","volume":"17","author":"Ruggeri","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0002","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/bmt.2015.162","article-title":"Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival","volume":"50","author":"Lunde","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0003","first-page":"12","article-title":"ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients","volume":"73","author":"Cesaro","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0004","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.bbmt.2018.04.009","article-title":"Efficacy of cidofovir in treatment of BK virus\u2013induced hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients","volume":"24","author":"Coomes","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.bbmt.2020.04.028_bib0005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/CMR.00074-16","article-title":"BK polyomavirus: clinical aspects, immune regulation, and emerging therapies","volume":"30","author":"Ambalathingal","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0006","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/bmt.2016.193","article-title":"The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"52","author":"Rimondo","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0007","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bbmt.2018.12.142","article-title":"Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation","volume":"25","author":"Copelan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0008","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.bbmt.2018.12.441","article-title":"Influence of the intensity of the allogeneic conditioning regimen on the risk of hemorrhagic cystitis (HC) in patients receiving post-transplant cyclophosphamide (PT-Cy) as GVHD prophylaxis","volume":"25","author":"Mukherjee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0009","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2016.07.030","article-title":"Review of advances in uroprotective agents for cyclophosphamide- and ifosfamide-induced hemorrhagic cystitis","volume":"100","author":"Matz","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0010","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2002.04.178","article-title":"2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology","volume":"20","author":"Schuchter","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.bbmt.2020.04.028_bib0011","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0041-1345(00)00906-4","article-title":"A new regimen of MESNA (2-mercaptoethanesulfonate) effectively prevents cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplant recipients","volume":"32","author":"Khojasteh","year":"2000","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0012","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/bmt.2015.197","article-title":"Continuous IV infusion of MESNA can prevent hemorrhagic cystitis in HSCT and retain MESNA concentration in urine","volume":"50","author":"Jiang","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0013","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1177\/106002809502900914","article-title":"Efficacy of MESNA for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy","volume":"29","author":"Haselberger","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0014","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/17474086.2017.1318054","article-title":"Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?","volume":"10","author":"Mussetti","year":"2017","journal-title":"Exp Rev Hematol"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0015","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0016","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0018","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbmt.2015.03.003","article-title":"Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0019","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0020","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/bmt.2015.289","article-title":"Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide","volume":"51","author":"Castagna","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0021","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0022","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12185-010-0569-x","article-title":"Cytomegalovirus infection\/disease after hematopoietic stem cell transplantation","volume":"91","author":"Mori","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0023","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3109\/10428194.2014.930849","article-title":"Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients","volume":"56","author":"Ferr\u00e0","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0024","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S1470-2045(14)70375-4","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0025","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0026","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0027","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0028","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0029","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0305-7372(83)80005-X","article-title":"The development of mesna for regional detoxification","volume":"10 Suppl A","author":"Brock","year":"1983","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0031","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1200\/JCO.1993.11.7.1306","article-title":"Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial","volume":"11","author":"Vose","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0032","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1200\/JCO.1991.9.11.2016","article-title":"Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation","volume":"9","author":"Shepherd","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0033","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0034","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.04.028_bib0035","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bbmt.2011.07.025","article-title":"Different risk factors related to adenovirus- or BK virus-associated hemorrhagic cystitis following allogeneic stem cell transplantation","volume":"18","author":"Mori","year":"2012","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120302834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:11:09Z","timestamp":1761059469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120302834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1083879120302834"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.028","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}